Literature DB >> 1620548

JAK2, a third member of the JAK family of protein tyrosine kinases.

A G Harpur1, A C Andres, A Ziemiecki, R R Aston, A F Wilks.   

Abstract

We have isolated cDNA clones encoding a third, widely expressed, member of the JAK family of protein tyrosine kinases (PTKs). The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs. The structural similarity of JAK2 to the other members of this family extends towards their N-termini, beyond the two kinase-related domains, and reveals five further domains of substantial amino acid similarity. The C-terminal portion of one of these domains, the JH4 domain, bears an intriguing, albeit tenuous, similarity to the core element of the SH2 domain, whereas the remaining JAK homology domains do not appear to be a feature of other known proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1620548

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  67 in total

1.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

Review 2.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

3.  STAT1 from the cell membrane to the DNA.

Authors:  B F Lillemeier; M Köster; I M Kerr
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

Review 4.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 5.  Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Authors:  Jacqueline Sayyah; Peter P Sayeski
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

Review 6.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 7.  Integration of cytokine and heterologous receptor signaling pathways.

Authors:  Jelena S Bezbradica; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

8.  Combining multiple structure and sequence alignments to improve sequence detection and alignment: application to the SH2 domains of Janus kinases.

Authors:  B Al-Lazikani; F B Sheinerman; B Honig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 9.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

10.  Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.

Authors:  Róbert Kiss; Tímea Polgár; Annet Kirabo; Jacqueline Sayyah; Nicholas C Figueroa; Alan F List; Lubomir Sokol; Kenneth S Zuckerman; Meghanath Gali; Kirpal S Bisht; Peter P Sayeski; György M Keseru
Journal:  Bioorg Med Chem Lett       Date:  2009-05-05       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.